| Congenital agammaglobulinemia
HyQvia vs Xembify
Side-by-side clinical, coverage, and cost comparison for congenital agammaglobulinemia.Deep comparison between: Hyqvia vs Xembify with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsXembify has a higher rate of injection site reactions vs Hyqvia based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xembify but not Hyqvia, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Hyqvia
Xembify
At A Glance
SC injection
Every 3-4 weeks
Immune globulin (IgG replacement)
SC injection
Daily to every 2 weeks
Immune globulin replacement
Indications
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Congenital agammaglobulinemia
- Wiskott-Aldrich Syndrome
- Severe Combined Immunodeficiency
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Primary immune deficiency disorder
- Congenital agammaglobulinemia
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Wiskott-Aldrich Syndrome
- Severe Combined Immunodeficiency
Dosing
Common Variable Immunodeficiency, X-linked agammaglobulinemia, Congenital agammaglobulinemia, Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency 300 to 600 mg/kg SC every 3 to 4 weeks after initial ramp-up from 1-week to full dose; rHuPH20 at 80 U/g IgG infused immediately before each IgG dose at each infusion site.
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Same dose and frequency as prior IGIV treatment SC, typical dosing interval 4 weeks; rHuPH20 at 80 U/g IgG infused immediately before each IgG dose; ramp-up recommended based on tolerability.
Primary immune deficiency disorder, Congenital agammaglobulinemia, Common Variable Immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency SC infusion only; treatment-naive: 150 mg/kg/day loading dose for 5 consecutive days, then 150 mg/kg/week maintenance starting Day 8; switching from IVIG: begin 1 week after last IVIG, initial weekly dose (g) = prior IVIG dose (g) x 1.37 / number of weeks between IVIG doses; switching from IGSC: administer same weekly dose (g) as prior IGSC; doses may be adjusted for frequent (2-7 times/week) or biweekly administration.
Contraindications
- History of anaphylactic or severe systemic reactions to IgG administration
- IgA deficiency with antibodies to IgA and a history of hypersensitivity
- Known systemic hypersensitivity to hyaluronidase including rHuPH20
- Known systemic hypersensitivity to human albumin (in the hyaluronidase solution)
- Previous anaphylactic or severe systemic reaction to human immune globulin
- IgA deficiency with antibodies against IgA and history of hypersensitivity to human immune globulin treatment
Adverse Reactions
Most common (>5%) Local infusion site reactions (discomfort/pain, erythema, swelling/edema, pruritus), headache, fatigue, nausea, pyrexia, vomiting
Postmarketing Hypersensitivity, influenza-like illness, infusion site leaking, anaphylactic reaction, tremor, tachycardia, hypotension, infusion related reaction, dyspnea, paresthesia oral, dermatitis allergic, injection site rash, alanine aminotransferase increased
Most common (>=5%) Infusion site erythema, infusion site pain, infusion site swelling, infusion site bruising, infusion site nodule, infusion site pruritus, infusion site induration, infusion site scab, infusion site edema, cough, diarrhea
Postmarketing Anaphylactic reaction, hypersensitivity, aseptic meningitis, dizziness, paresthesia, tachycardia, hypotension, dyspnea, chest discomfort, injection site reactions, chills, fatigue, pain, tremor, laryngospasm
Pharmacology
Immune globulin (IgG) replacement product in which the Immune Globulin Infusion (Human), 10% supplies broad-spectrum opsonizing and neutralizing IgG antibodies against bacterial and viral agents, while rHuPH20 transiently depolymerizes subcutaneous hyaluronan to increase tissue permeability, facilitating dispersion and absorption of the full IgG dose administered subcutaneously.
XEMBIFY supplies a broad spectrum of opsonizing and neutralizing IgG antibodies against bacterial, viral, parasitic, and mycoplasmal agents and their toxins, and contains antibodies capable of interacting with and altering the activity of immune system cells, though the full mechanism is not completely understood.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Hyqvia
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (0/12)
Xembify
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (0/12)
UnitedHealthcare
Hyqvia
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (0/8)
Xembify
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Hyqvia
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Xembify
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Primary Immune Deficiency - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
HyqviaView full Hyqvia profile
XembifyView full Xembify profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.